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Abstract
Background: These data compare the efficacy and safety of highly purified human-derived follicle-stimulating
hormone (Bravelle(R)) and recombinant follitropin-β (Follistim(R)) in women undergoing in vitro fertilization.
Methods: This report describes the pooled data from two, nearly identical, randomized, controlled, parallel-
group, multicenter studies conducted in a total of 19 academic and private IVF-ET centers in the United States.
Infertile premenopausal women underwent pituitary down-regulation using leuprolide acetate followed by a
maximum of 12 days of subcutaneous Bravelle(R) (n = 120) or Follistim(R) (n = 118), followed by administration
of human chorionic gonadotropin, oocyte retrieval and embryo transfer. The primary efficacy measure was the
mean number of oocytes retrieved; secondary efficacy measures included the total dose and duration of
gonadotropin treatment; peak serum estradion levels; embryo transfer and implantation rates; chemical, clinical
and continuing pregnancies; and live birth rates. All adverse events were recorded and injection site pain was
recorded daily using a patient, self-assessment diary.
Results: Similar efficacy responses were observed for all outcome parameters in the two treatment groups.
Although patients receiving Bravelle(R) consistently reported a greater number of chemical, clinical and continuing
pregnancies, as well as an increased rate of live birth, the data did not attain statistical significance (P > 0.05). The
overall incidence of adverse events was similar in both groups, but compared to Follistim(R), injections of
Bravelle(R) were reported by patients to be significantly less painful (P < 0.001).
Conclusions: Bravelle(R) and Follistim(R) had comparable efficacy in controlled ovarian hyperstimulation in
women undergoing IVF-ET. There were no differences in the nature or number of adverse events between the
treatment groups although Bravelle(R) injections were reported to be significantly less painful.
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Introduction
Following their discovery in the 1920s, the pituitary gona-
dotropins, follicle-stimulating hormone (FSH) and lutei-
nizing hormone (LH), were first used successfully for
ovulation induction in 1958 [1]. Since then, exogenous
hormone preparations of these gonadotropins have been
widely used for the treatment of oligoanovulatory infertil-
ity, as well as for stimulation of multiple follicular devel-
opment in assisted reproductive techniques.
The first commercially available gonadotropin prepara-
tion, human menopausal gonadotropin (hMG), was puri-
fied from the urine of postmenopausal women and
contained equal amounts of FSH and LH activity [2]. With
the development of sophisticated purification techniques
[3], more purified FSH preparations containing small
amounts of LH became available in 1986. Thereafter, a
highly purified FSH preparation was developed and
approved for use in 1996.
Advances in molecular biology techniques made it possi-
ble to produce recombinant FSH, which is secreted from
genetically engineered Chinese hamster ovary cells [4].
Despite identical amino acid sequences, recombinant and
natural FSH preparations have different glycosylation pat-
terns, which are known to influence the isoform profile of
each product [5,6]. The clinical implications of differing
isoform profiles for FSH products are unclear and there
are no convincing data to suggest marked superiority of
either human-derived or animal-derived FSH formula-
tions for ovarian stimulation in terms of efficacy or safety
[7–14]. Nonetheless, since subtle differences due exist
between human derived and recombinant forms of FSH,
efforts continue to identify clinically relevant differences
between the two FSH preparations.
This report presents the pooled data from two independ-
ent trials, nearly identical in design, which compared the
efficacy and safety of highly purified human-derived FSH
(Bravelle®) with recombinant follitropin-β (Follistim®),
administered subcutaneously in infertile women with reg-
ular ovulatory menstrual cycles undergoing in vitro fertili-
zation procedures. The present data form part of the
clinical development program describing the comparative
efficacy and safety of Bravelle®, the newest approved,
highly purified (96–98%), human-derived FSH which
contains ≤ 2% LH activity.
Materials and Methods
Two randomized, parallel group, clinical trials (one
recently published [8]) compared single cycle treatment
with subcutaneously administered, purified, human-
derived FSH (Bravelle®; n = 120) vs. recombinant follitro-
pin-β (Follistim®; n = 118) in infertile female patients
undergoing IVF. Data were collected from 19 IVF-ET cent-
ers, each of which obtained institutional review board
approval. Eleven centers participated in the first study
while 13 centers participated in the second study. Both
studies were conducted in accordance with Good Clinical
Practice guidelines and written informed consent was
obtained from all participants prior to screening and
enrollment.
Patients were non-smoking, infertile, premenopausal
females, aged 18–39 years, with body mass index (BMI) ≤
34 kg/m2 and regular ovulatory menstrual cycles (24–35
days). Causes of infertility were attributed to tubal factor,
endometriosis (American Fertility Society revised stage I
or II) or unexplained. Participants had ultrasound-con-
firmed normal ovaries with healthy uterus and adnexae.
Further eligibility criteria included: unremarkable medical
history and physical examination with normal baseline
hematology and clinical chemistry; normal range serum
estradiol (E2), follicle stimulating hormone (FSH), lutein-
izing hormone (LH), testosterone, dihydroepiandroster-
one sulfate, prolactin and thyroid stimulating hormone.
All patients needed to be seronegative for hepatitis B and
C, HIV and syphilis and have a negative pregnancy test
before starting treatment. Male partner or donor semen
was required to meet World Health Organization criteria
[15] for normal, within 6 months of study entry.
Patients who fulfilled screening criteria were instructed to
inject leuprolide acetate (TAP Pharmaceuticals, Deerfield,
IL), 0.5 mg subcutaneously each morning, for pituitary
down-regulation. Leuprolide acetate was injected into the
thigh or arm, beginning 7 days before the anticipated
onset of menses and administration continued for ≤ 20
days or until their serum E2 concentration was ≤ 45 pg/mL
and endometrial thickness was ≤ 7 mm on transvaginal
ultrasound. If no menstrual bleeding occurred during this
time, the patient was withdrawn from the trial, otherwise,
leuprolide acetate was continued at the same dose until
the day before hCG (Novarel™, Ferring Pharmaceuticals,
Inc, Suffern, New York) administration.
Patients who met pituitary down-regulation requirements
were randomized, using randomization codes generated
with SAS® Proc Plan, to receive Bravelle® (n = 120; Ferring
Pharmaceuticals, Inc, Suffern, New York) or Follistim® (n
= 118; Organon Inc., West Orange, New Jersey) once
daily, in a dose of 225 IU, subcutaneously, for 5 days.
Study center staff administered the first dose of gonado-
tropin and provided guidance on abdominal injection
technique, including alternation of injection sites, for sub-
sequent dosing at home. Patients were instructed to main-
tain a daily, gonadotropin diary of the injection site and
the presence and intensity of any pain.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/63
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After the initial 5 days of FSH treatment, ovarian response
was evaluated by transvaginal ultrasound and serum E2
concentrations. If necessary, the dose of gonadotropin
was increased in increments of 75–150 IU/day on alter-
nate days, to a maximum of 450 IU/day. The duration of
the controlled ovarian hyperstimulation cycle was not to
exceed 12 days. At their discretion, investigators could
reduce the dose or discontinue treatment at any time if
concerned about patient safety.
Eligibility criteria for Novarel™ administration were the
presence of at least three follicles with a diameter of ≥ 16
mm, calculated as the mean of three perpendicular planes
by transvaginal ultrasound, along with a serum E2 level
that was judged by the investigator to be appropriate for
the number of follicles. A single dose of 10,000 IU USP
Novarel™ was administered intramuscularly, 1 day after
the final dose of gonadotropin. Patients who had not
achieved eligibility criteria for Novarel™ treatment follow-
ing a maximum of 12 days of gonadotropin stimulation
were allowed to 'coast' for a further 2 days. If the follicular
response remained suboptimal, participants were consid-
ered non-responders and were withdrawn from the trial.
Standard site-specific procedures were used for oocyte
retrieval and IVF-ET. Intracytoplasmic sperm injection
(ICSI) and assisted hatching were prohibited. A maximum
of four embryos were allowed to be transferred to each
patient. Progesterone for luteal phase support was either
self-administered (Crinone™ 8%, 90 mg q.d., Serono Lab-
oratories Inc, Randolph, MA) or administered in the form
of progesterone in oil (50 mg, i.m., q.d., Schein Pharma-
ceuticals, Florham Park, NJ), beginning 2 or 3 days after
oocyte retrieval. Luteal phase support was maintained at
least until there was fetal heart motion in an intrauterine
pregnancy or a negative pregnancy test (β-hCG) was doc-
umented. The first serum pregnancy test was performed
14 days after embryo transfer and, if positive, was fol-
lowed by a confirmatory β-hCG measurement 2 days
later. Transvaginal ultrasound was performed approxi-
mately 2 weeks later to verify a clinical pregnancy (gesta-
tional sac and fetal heart motion) and repeated 1 week
later to confirm a continuing pregnancy.
The primary efficacy parameter for this single-cycle analy-
sis was the number of oocytes retrieved. Secondary effi-
cacy variables included the percentage of cycles with
oocyte retrieval; duration of gonadotropin therapy; total
FSH dose; peak serum E2 levels; embryo transfer and
implantation rates; chemical pregnancies (positive serum
β-hCG); clinical pregnancies (intrauterine gestational sac
with fetal heart motion); continuing pregnancies and live
birth rates.
Statistical Analysis
The validity of pooling data from the two independent
studies was confirmed by statistical examination, which
concluded that the two studies were homogeneous by
excluding treatment-by-study interaction for the number
of oocytes retrieved, using an ANOVA model with factors
for 'treatment', 'study' and 'treatment-by-study' interac-
tion. The treatment-by-study interaction was not statisti-
cally significant (P = 0.87) and a fixed effects approach
was therefore appropriate for data analysis. Data were
pooled and adjusted using the 'study' variable as a fixed
effect, to account for between-study variability.
Safety was evaluated by analysis of the nature and inci-
dence of adverse events, irrespective of their relation to
study medications. Injection site pain was self-rated using
a daily diary with an analog scale of 1 (no pain) to 10
(severe or unbearable pain).
For the first study, sample size calculations were based on
the clinical assumption that 10 oocytes per patient would
be retrieved in the reference group. Power calculations
were based on an α level of 0.05 (two-tailed test) with
80% power to detect a 30% difference with 50 evaluable
patients per group. A sample of 60 patients per group was
selected. For the second study, the assumption for the
number of oocytes retrieved from the reference group was
changed to 13.7, based on the results of the first study. The
power calculation was based on an α level of 0.025 (one-
tailed test) with 80% power to detect a 30% difference
with 56 evaluable patients per group.
Continuous variables, including primary and secondary
outcome parameters, were analyzed using a two-way
ANOVA model with treatment and study as fixed effects.
In addition, an analysis of covariance (ANCOVA) model
was used to compare primary and secondary efficacy vari-
ables after correcting for baseline age and BMI. The differ-
ence between treatments (Bravelle® vs. Follistim®) was
evaluated using a one-sided, 95% confidence interval.
Bravelle® could be declared equivalent in terms of efficacy
if the lower limit of the 95% confidence interval was
greater than a difference of -2.2 oocytes.
Categorical variables, including adverse events, were com-
pared using Cochran-Mantel-Haenszel (CMH) analyses,
stratified by study, and a logistic regression model using
treatment, study, baseline age and BMI as covariates.
Injection site pain scores on each day were compared
using the two-way ANOVA model with treatment and
study as fixed effects and also using a linear mixed model
to compare data across all time points. The latter allowed
analysis of continuous data to account for intrasubject
variability. The Restricted Maximum Likelihood MethodReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/63
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was used with a compound symmetric within-subject cov-
ariant structure, and the sandwich variance estimator.
Results
A total of 323 patients were enrolled in the two studies
and received leuprolide acetate for pituitary down-regula-
tion, 297 were randomized between the study arms. The
most common reasons for non-randomization was failure
to down-regulate to the protocol-specified criteria or
patients had a positive pregnancy test prior to down-regu-
lation on LA therapy. The initial study contained a third
arm consisting of 59 patients, which are not included in
this pooled analysis. The remaining 238 patients were
randomized to receive Bravelle® (n = 120) or Follistim® (n
= 118).
In the Bravelle and Follistim groups, 94.2% and 97.5% of
women respectively, received Novarel™ and underwent
oocyte retrieval. Since nearly all randomized patients
received Novarel™, there were no clinically or statistically
meaningful differences between the intent-to-treat analy-
sis and the primary efficacy responders (those who
received Novarel™) analyses. Therefore, efficacy data pre-
sented in this report are based on the primary efficacy
responder population for the primary efficacy parameter,
number of oocytes retrieved, and subsequent analyses.
Baseline demographic characteristics and safety data com-
parisons are presented for all enrolled patients regardless
of administration of Novarel™.
Demographic and baseline data, including endocrine sta-
tus, primary infertility diagnosis and IVF history are pre-
sented in Table 1. The groups were generally well matched
demographically, although women in the Bravelle® group
had a significantly lower mean weight, and therefore
lower BMI (23.3 vs. 24.5 kg/m2, respectively, P = 0.021).
The modest difference in BMI was not considered to be
clinically meaningful, in addition, for the ANCOVA anal-
ysis of efficacy parameters, BMI and age were used as cov-
ariates to account for the effect these differences may have
had on outcomes.
During the course of treatment, there was no statistically
significant differences between groups for the primary
efficacy measure, mean number of oocytes retrieved per
cycle, the numbers of oocytes that underwent normal fer-
tilization or the number of embryos transferred (Figure
1). The implantation rate did not differ between groups,
as it was 21.3% for the Bravelle® group and 20.3% for the
Follistim® group.
No significant differences were observed in the total dose
of FSH administered, the duration of treatment or peak
estradiol levels between groups (Table 2). Patients receiv-
ing Bravelle® had a numerical trend towards higher chem-
ical, clinical, continuing pregnancy rates as well as live
birth rates (Figure 2), but the results did not attain statis-
tical significance.
Table 1: Baseline demographic characteristics (prior to leuprolide acetate) of the 120 patients who received Bravelle® and the 118 
patients who received Follistim®
Parameter Bravelle® (n = 120) Follistim® (n = 118) P-value
Age (years) 32.0 ± 3.9 32.5 ± 3.7 0.330
Weight (lbs.) 137.1 ± 21.4 145.8 ± 27.8 0.008
Body mass index (kg/m2) 23.3 ± 3.5 24.5 ± 4.0 0.021
Serum FSH (mIU/mL) 6.3 ± 2.0 6.8 ± 2.1 0.077
Serum LH (mIU/mL) 5.0 ± 2.4 4.6 ± 1.9 0.145
Serum E2 (pg/mL) 43.1 ± 21.4 40.9 ± 20.9 0.420
Primary infertility diagnosis
Tubal Factor 50.0 55.9 0.361
Endometriosis 17.5 14.4 0.508
Unexplained 28.3 22.9 0.341
Male factor 4.2 3.4 0.752
Fertility history (%)
Full term birth (s) 23.3 31.4 0.087
Abortion(s)/miscarriage(s) 30.8 39.0 0.142
Gonadotropin cycles (excluding
IVF/GIFT/PROST)
25.8 25.4 0.889
Previous IVF/GIFT/PROST 27.5 22.9 0.422
Data are means ± SD.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/63
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There were no significant differences in the number of
patients reporting adverse events (P = 0.680), severe
adverse events (P = 0.307) or serious adverse events (P =
0.161) between the Bravelle® or Follistim® groups. The
most frequently reported adverse events were headache,
abdominal cramps, vaginal bleeding/spotting and nausea
(Table 3). One woman taking Bravelle® experienced a
'severe' adverse event, compared with three patients in the
Follistim® group. 'Serious' adverse events were reported by
two patients in the Bravelle® group.
A two-way ANOVA model used to compare mean daily
injection-site pain revealed a significantly lower pain
score in Bravelle® patients on most treatment days and
during the entire treatment period (P < 0.05). The differ-
ence had greater significance when a linear mixed model,
which controls for intrasubject variation, was used to
compare data across all time points [3.1 and 3.9, respec-
tively (P < 0.001)] (Figure 3).
Discussion
The data from these two randomized, controlled, clinical
studies were used to evaluate the efficacy and safety of a
new, highly purified, human derived FSH (Bravelle®)
compared to follitropin-β (Follistim®) in patients under-
going controlled ovarian hyperstimulation for IVF-ET. Cli-
nicians continually update their safety and efficacy data as
patients are treated, in order to better understand their
treatment protocols. This paper is a similar exercise in that
it combines two regulatory grade IVF studies to confirm
the efficacy and safety results from the previous study (8).
The fact that the results and conclusions of the second
study are similar to the first further highlights the consist-
ency and reliability of Bravelle® in patients undergoing in
vitro fertilization.
The baseline weight and BMI differences between Brav-
elle® and Follistim® patients were modestly different, but
were unlikely to have affected trial outcomes since neither
group could be categorized as obese (BMI ≥ 28 kg/m2) or
underweight (BMI < 20 kg/m2), variables thought to cor-
Clinical response for the 113 patients that received Bravelle® (black bars) and the 115 patients that received Follistim® (gray  bars) Figure 1
Clinical response for the 113 patients that received Bravelle® (black bars) and the 115 patients that received Follistim® (gray 
bars). Mean value per patient of oocytes retrieved, oocytes fertilized and embryos transferred.
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relate with reduced success during assisted conception
[16–18]. Nonetheless, an ANCOVA analysis was per-
formed using BMI and age as covariates, to ensure that the
difference in BMI did not effect outcome measures.
Recombinant DNA engineering technology allows for the
production of human FSH in Chinese hamster ovary cells
[4]. The secreted protein is collected from the culture
medium and purified. Efforts have been made in an
attempt to identify differences in efficacy between recom-
binant and human derived gonadotropin preparations. It
is recognized that differences exist in the glycosylation
patterns of these preparations [5,6]. However, collectively,
the results from numerous, prospective, clinical studies
[7–14], and recent meta-analyses [19,20] of published
Pregnancy and live birth results for the 113 patients that received Bravelle® (black bars) and the 115 patients that received  Follistim® (gray bars) Figure 2
Pregnancy and live birth results for the 113 patients that received Bravelle® (black bars) and the 115 patients that received 
Follistim® (gray bars).
Table 2: Clinical response for the 120 patients who received Bravelle® and the 118 patients who received Follistim®.
Parameter Bravelle® (n = 120) Follistim® (n = 118) P-value
Day 1 of stimulationa
Serum FSH (mIU/mL) 4.6+1.7 4.9+2.2 0.155
Serum LH (mIU/mL) 4.6+2.9 4.6+2.6 0.894
Serum E2 (pg/mL) 23.7 +11.8 22.6 +10.4 0.442
Mean days of FSH therapy 9.1 ± 1.6 9.2 ± 1.5 0.645
Mean total dose of FSH (IU) 2313.8 ± 837.1 2262.7 ± 736.8 0.613
Mean peak estradiol levels (pg/mL) 1893.4 ± 1154.8 1888.9 ± 1131.9 0.817
Data are means ± SD. There were no significant differences between groups on any parameter. aSerum levels taken on the first day of gonadotropin 
stimulation.
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data have failed to show any meaningful or reproducible
differences.
Nonetheless, it is well known that the success of a control-
led ovarian hyperstimulation cycle is in part dependent
on the presence of LH. Bravelle® provides a low level of LH
activity which might benefit certain patients by enhancing
intrafollicular estradiol levels, resulting in the excellent
single cycle pregnancy rates observed in this analysis. The
presence of small amounts of LH activity may be of spe-
cific benefit in patients with low endogenous LH levels
that undergo pituitary down regulation. Overall, Bravelle®
provides a safe and highly effective alternative to gonado-
tropins devoid of LH activity.
Table 3: Summary of adverse events
No.(%) of patients
Patients Bravelle® (n = 120) Follistim® (n = 118)
With any adverse event 73 (60.8) 75 (63.6)
With serious or severe adverse eventa 3 (2.5) 3 (2.5)
With most frequently reported adverse eventsb
Vaginal spotting/hemorrhage 11 (9.2) 16 (13.6)
Headache 18 (15.0) 17 (14.4)
Abdominal cramps 17 (14.2) 20 (16.9)
Nausea 12 (10.0) 15 (12.7)
Abdominal pain 6 (5.0) 10 (8.5)
Pelvic pain/cramps 8 (6.7) 6 (5.1)
OHSS 6 (5) 6 (5.1)
aIn the Bravelle® group, one patient had an ectopic pregnancy that was resolved through surgery. One patient had a case of OHSS that was deemed 
severe in nature and required hospitalization. It was resolved without sequelae. One other patient had OHSS that was deemed moderate in nature, 
at the time of resolution, she had a continuing twin pregnancy. In the Follistim® group, there were three patients that had OHSS, all deemed mild in 
nature, one of which had a continuing pregnancy at the time of resolution. bThis tabulation involves adverse events, regardless of relationship to 
treatment, that occurred in either treatment group.
Comparison of injection site pain scores on a self-assessment scale of 0 (no pain) to 10 (severe pain) for the 113 patients that  received Bravelle® (black bars) and the 115 patients that received Follistim® (gray bars) Figure 3
Comparison of injection site pain scores on a self-assessment scale of 0 (no pain) to 10 (severe pain) for the 113 patients that 
received Bravelle® (black bars) and the 115 patients that received Follistim® (gray bars).
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The adverse event data from this study demonstrate that
Bravelle® is at least as well tolerated as Follistim®, but
causes significantly less injection-related pain. This find-
ing, reported in a previous study [8] may be related to the
purity of Bravelle® and the differences in excipients used in
the manufacturing processes for the two compounds. For
example, Follistim® contains sodium citrate which has
previously been implicated with injection site pain by
some [22] while Bravelle® does not.
In conclusion, this analysis further supports the clinical
data indicating the comparable efficacy and overall safety
of Bravelle® as compared to Follistim® in controlled ovar-
ian hyperstimulation for IVF-ET, and highlights the poten-
tial benefit of Bravelle® which produced less injection site
pain.
Author contributions
Dr.'s Dickey, Nichols, Steinkampf, Gocial, Thornton,
Webster, Bello and Crain contributed to the treatment of
patients and collection of data.
Acknowledgements
Other members of the Bravelle® IVF study group are: Frankfurter, D, 
Women's and Infants Hospital, Providence, RI; Gorrill, M, Oregon Health 
Science University, Women's Health Research Unit, Portland, OR; 
Katayama, P, Advanced Institute of Fertility, Milwaukee, WI; Kettel, M, San 
Diego Fertility Center, San Diego, CA; Kort, H, Reproductive Biology 
Associates, Atlanta, GA; Kutteh, W, University of Tennessee, Memphis, 
TN; Magarelli, P, Reproductive Medicine and Fertility Center, Colorado 
Springs, CO; Najmabadi, S, Center for Repoductive Health and Gynecol-
ogy, Valencia, CA; Patton, G, Southeastern Fertility Center, PA, Mount 
Pleasant, SC; Somkuti, S, Abington Reproductive Medicine, PC, Abington, 
PA; Yeko, T, Verkauf, Bernhisel, Tarantino, Goodman and Yeko, MDs, PA, 
Tampa, FL.
References
1. Gemzell C, Diczfalusy E and Tillinger K: Clinical effects of human
pituitary follicle stimulating hormone. J Clin Endocrinol Metab
1958, 18:1333-1348.
2. Lunenfeld B, Sulimovici S, Rabau E and Eshkol A: L'induction de
l'ovulation dans les amenorrhees hypophysaies par un traite-
ment combiné de gonadotropines urinaires ménopausiques
et de gonadotropines chorioniques.  Soc Fr Gynecol 1962,
5:346-351.
3. Donini P, Puzzuoli D, D'Alessio I, Lunenfeld B, Eshkol A and Parlow
AF: Purification and separation of follicle stimulating hor-
mone (FSH) and luteinizing hormone (LH) from human
postmenopausal gonadotropin (HMG). II. Preparation of
biological apparently pure FSH by selective binding of the
LH with an anti-HCG serum and subsequent
chromatography. Acta Endocrinol (Copenh) 1966, 52:186-198.
4. Sairam M and Sebok K: Pharmacokinetics of natural/recom-
binant FSH (follitropin) and some analogs. In: Ovulation Induc-
tion: Basic Science and Clinical Advances Edited by: Filicori M, Flamigni C.
Amsterdam: Excerpta Medica; 1994:199-208. 
5. Matikainen T, De Leeuw R, Mannaerts B and Huhtaniemi I: Circulat-
ing bioactive and immunoreactive recombinant human folli-
cle stimulating hormone (Org 32489) after administration to
gonadotropin-deficient subjects. Fertil Steril 1994, 61:62-69.
6. Fauser B, Rutherford A, Strauss J, Van Steirteghem A and Eds: In:
Gonadotrophin receptors: Molecular biology in reproductive medicine New
York, NY: Parthenon Publishing Group; 1999:165-200. 
7. Selman H, De Santo M, Sterzik K, Coccia E and El-Danasouri I: Effect
of highly purified urinary follicle-stimulating hormone on
oocyte and embryo quality. Fertil Steril 2002, 78:1061-1067.
8. Dickey R, Thornton M, Nichols J, Marshall D, Fein S, Nardi R and for
the Bravelle™ IVF Study Group: Comparison of the efficacy and
safety of a highly purified human follicle-stimulating hor-
mone (Bravelle™) and recombinant follitropin-β for in vitro
fertilization: a prospective, randomized study. Fertil Steril 2002,
77:1202-1208.
9. Ravhon A, Lavery S, Aurell R, Trew G, Margara R and Winston R:
Clinical experience with recombinant follicle-stimulating
hormone (FSH) and urinary FSH: a retrospective case-con-
trolled analysis. Fertil Steril 2001, 75:920-925.
10. Franco J, Baruffi R, Coelho J, Mauri A, Petersen C and Garbellini E: A
prospective and randomized study of ovarian stimulation for
ICSI with recombinant FSH versus highly purified urinary
FSH. Gynecol Endocrinol 2000, 14:5-10.
11. Lenton E, Soltan A, Hewitt J, Thomson A, Davies W, Ashraf N,
Sharma V, Jenna L, Ledger W and McVeigh E: Induction of ovula-
tion in women undergoing assisted reproductive techniques:
recombinant human FSH (follitropin alpha) versus highly
purified urinary FSH (urofollitropin HP). Hum Reprod 2000,
15:1021-1027.
12. Bergh C, Howles C, Borg K, Hamberger L, Josefsson B, Nilsson L and
Wikland M: Recombinant human follicle stimulating hormone
(r-hFSH ; Gonal F) versus highly purified urinary FSH (Met-
rodin HP): results of a randomized comparative study in
women undergoing assisted reproductive techniques. Hum
Reprod 1997, 12:2133-2139.
13. Recombinant Human FSH Study Group: Clinical assessment of
recombinant human follicle-stimulating hormone in stimu-
lating ovarian follicular development before in vitro
fertilization. Fertil Steril 1995, 63:77-86.
14. Feigenbaum S, Miller P, Kaufmann R, Elkind-Hirsch K, Fein S and Mar-
shall D: A new highly purified human-derived FSH, Brav-
elle™, is as effective and well-tolerated as recombinant
follitropin beta in ovulation induction in infertile women
with ovulatory dysfunction.  Today's Therapeutic Trends 2001,
19:297-313.
15. World Health Organisation: . Laboratory manual for the examination of
human semen and sperm cervical mucus interaction 4th edition. Cam-
bridge: Cambridge University Press; 1999. 
16. Wittemer C, Ohl J, Bailly M, Bettahar-Lebugle K and Nisand I: Does
body mass index of infertile women have an impact on IVF
procedure and outcome? J Assist Reprod Genet 2000, 17:547-552.
17. Loveland JB, McClamrock H, Malinow A and Sharara F: Increased
body mass index has a deleterious effect on in vitro fertiliza-
tion outcome. J Assist Reprod Genet 2000, 18:382-386.
18. Salha O, Dada T and Sharma V: Influence of body mass index and
self-administration of hCG on the outcome of IVF cycles: a
prospective cohort study. Hum Fertil(camb) 2001, 4:37-42.
19. Van Wely M, Bayram N and van der Veen F: Recombinant FSH in
alternative doses or versus uinary gonadotrophins for ovula-
tion induction in subfertility associted with polycystic ovary
syndrome: a systematic review based on a Cochrane review.
Hum Reprod 2003, 18:1143-1149.
20. Al-Inany H, Aboulghar M, Mansour R and Serour G: Meta-analysis
of recombinant versus urinary-derived FSH: an update. Hum
Reprod 2003, 18:305-313.
21. Fevold HL: Synergism of the follicle stimulating and luteiniz-
ing hormones in producing estrogen secretion. Endocrinology
1941, 28:33-36.
22. Yu AW, Leung CB, Li PK, Lui SF and Lai KN: Pain perception fol-
lowing subcutaneous injections of citrate-buffered and phos-
phate-buffered epoetin alpha. Int J Artif Organs 1998, 21:341-343.